RAF-MEK-ERK pathway inhibitors to treat cancer
US7307071B2 · kind B2 · utility
22Cited by
4References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2002 |
| Grant date | Dec 11, 2007 |
| Priority date | — |
| Expiry date | Apr 6, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.